dc.creator | Aloizou A.-M., Pateraki G., Siokas V., Mentis A.-F.A., Liampas I., Lazopoulos G., Kovatsi L., Mitsias P.D., Bogdanos D.P., Paterakis K., Dardiotis E. | en |
dc.date.accessioned | 2023-01-31T07:31:02Z | |
dc.date.available | 2023-01-31T07:31:02Z | |
dc.date.issued | 2020 | |
dc.identifier | 10.1016/j.toxrep.2020.11.001 | |
dc.identifier.issn | 22147500 | |
dc.identifier.uri | http://hdl.handle.net/11615/70460 | |
dc.description.abstract | Gliomas are the most common primary brain tumors in adults. They are generally very resistant to treatment and are therefore associated with negative outcomes. MicroRNAs (miRNAs) are small, non-coding RNA molecules that affect many cellular processes by regulating gene expression and, post-transcriptionally, the translation of mRNAs. MiRNA-21 has been consistently shown to be upregulated in glioma and research has shown that it is involved in a wide variety of biological pathways, promoting tumor cell survival and invasiveness. Furthermore, it has been implicated in resistance to treatment, both against chemotherapy and radiotherapy. In this review, we gathered the existent data on miRNA-21 and gliomas, in terms of its expression levels, association with grade and prognosis, the pathways it involves and its targets in glioma, and finally how it leads to treatment resistance. Furthermore, we discuss how this knowledge could be applied in clinical practice in the years to come. To our knowledge, this is the first review to assess in extent and depth the role of miRNA-21 in gliomas. © 2020 | en |
dc.language.iso | en | en |
dc.source | Toxicology Reports | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85096106197&doi=10.1016%2fj.toxrep.2020.11.001&partnerID=40&md5=b1c4883f9d2ac53683e32c95f6746997 | |
dc.subject | apoptotic protease activating factor 1 | en |
dc.subject | caspase 3 | en |
dc.subject | cyclin D | en |
dc.subject | cyclin D1 | en |
dc.subject | DNA topoisomerase (ATP hydrolysing) | en |
dc.subject | doxorubicin | en |
dc.subject | galectin 1 | en |
dc.subject | gelatinase B | en |
dc.subject | granzyme B | en |
dc.subject | hyaluronic acid | en |
dc.subject | liposome | en |
dc.subject | lomustine | en |
dc.subject | microRNA | en |
dc.subject | microRNA 21 | en |
dc.subject | nimotuzumab | en |
dc.subject | paclitaxel | en |
dc.subject | protein Bax | en |
dc.subject | protein p53 | en |
dc.subject | small interfering RNA | en |
dc.subject | temozolomide | en |
dc.subject | teniposide | en |
dc.subject | transcription factor Sox2 | en |
dc.subject | tumor necrosis factor | en |
dc.subject | vasculotropin | en |
dc.subject | angiogenesis | en |
dc.subject | animal experiment | en |
dc.subject | apoptosis | en |
dc.subject | Article | en |
dc.subject | astrocyte | en |
dc.subject | astrocytoma | en |
dc.subject | autism | en |
dc.subject | bioinformatics | en |
dc.subject | blood brain barrier | en |
dc.subject | brain cancer | en |
dc.subject | brain ischemia | en |
dc.subject | brain tumor | en |
dc.subject | cancer prognosis | en |
dc.subject | cancer surgery | en |
dc.subject | cancer survival | en |
dc.subject | carcinogenesis | en |
dc.subject | carcinogenicity | en |
dc.subject | cell differentiation | en |
dc.subject | cell invasion | en |
dc.subject | cell migration | en |
dc.subject | cell proliferation | en |
dc.subject | cell survival | en |
dc.subject | cell viability | en |
dc.subject | chemotherapy | en |
dc.subject | disease free survival | en |
dc.subject | DNA damage | en |
dc.subject | drug delivery system | en |
dc.subject | enzyme inhibition | en |
dc.subject | exosome | en |
dc.subject | external beam radiotherapy | en |
dc.subject | fluorescence in situ hybridization | en |
dc.subject | gene overexpression | en |
dc.subject | genetic transcription | en |
dc.subject | glioblastoma | en |
dc.subject | glioma | en |
dc.subject | human | en |
dc.subject | hypoxia | en |
dc.subject | IC50 | en |
dc.subject | inflammation | en |
dc.subject | lipophilicity | en |
dc.subject | MAPK signaling | en |
dc.subject | melanoma | en |
dc.subject | metastasis | en |
dc.subject | microglia | en |
dc.subject | neural stem cell | en |
dc.subject | nonhuman | en |
dc.subject | nuclear magnetic resonance imaging | en |
dc.subject | nuclear reprogramming | en |
dc.subject | ovary cancer | en |
dc.subject | overall survival | en |
dc.subject | oxidative stress | en |
dc.subject | pancreas cancer | en |
dc.subject | protein expression | en |
dc.subject | protein function | en |
dc.subject | radiosensitivity | en |
dc.subject | radiosensitization | en |
dc.subject | scientific literature | en |
dc.subject | signal transduction | en |
dc.subject | tumor cell | en |
dc.subject | tumor growth | en |
dc.subject | tumor invasion | en |
dc.subject | tumor suppressor gene | en |
dc.subject | tumor volume | en |
dc.subject | tumor xenograft | en |
dc.subject | upregulation | en |
dc.subject | Elsevier Inc. | en |
dc.title | The role of MiRNA-21 in gliomas: Hope for a novel therapeutic intervention? | en |
dc.type | journalArticle | en |